Dogwood Therapeutics’ (DWTX) Buy Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Dogwood Therapeutics (NASDAQ:DWTX) in a report issued on Friday morning,Benzinga reports. HC Wainwright currently has a $12.00 target price on the stock.

DWTX has been the topic of several other research reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Dogwood Therapeutics in a research report on Monday, December 22nd. Wall Street Zen cut shares of Dogwood Therapeutics to a “strong sell” rating in a research note on Saturday, December 13th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $12.00.

Dogwood Therapeutics Stock Performance

Dogwood Therapeutics stock opened at $2.93 on Friday. The business’s fifty day moving average is $3.62 and its two-hundred day moving average is $4.94. The firm has a market cap of $93.99 million, a P/E ratio of -0.12 and a beta of 1.88. Dogwood Therapeutics has a 52 week low of $2.60 and a 52 week high of $14.69.

Institutional Investors Weigh In On Dogwood Therapeutics

An institutional investor recently bought a new position in Dogwood Therapeutics stock. Marshall Wace LLP acquired a new stake in Dogwood Therapeutics, Inc (NASDAQ:DWTX) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 11,655 shares of the company’s stock, valued at approximately $48,000. Marshall Wace LLP owned about 0.51% of Dogwood Therapeutics at the end of the most recent quarter. Hedge funds and other institutional investors own 9.05% of the company’s stock.

Dogwood Therapeutics Company Profile

Dogwood Therapeutics is a clinical‐stage biotechnology company dedicated to the discovery and development of novel biologic therapies aimed at reducing fibrosis and promoting tissue repair in cardiovascular and other fibrotic diseases. The company leverages a proprietary Discovery Engine that integrates high‐throughput screening, functional genomics and protein engineering to identify and optimize candidate proteins and antibodies with therapeutic potential.

Dogwood’s lead programs are focused on preventing adverse cardiac remodeling following myocardial injury and improving outcomes in heart failure patients.